NCT07419516Completed
MRA Diameter as a Predictor for LLN Metastasis in Rectal Cancer.
Middle Rectal Artery Diameter as a Predictor for Lateral Lymph Node Metastasis in Rectal Cancer: A Predictive Model for Surgical Decision-Making.
Source: ClinicalTrials.gov · Last updated 19 Feb 2026
Brief summary (registry, in English)
This study aims to identify risk factors-including clinical and imaging indicators such as middle rectal artery (MRA) diameter-that may be associated with lateral lymph node metastasis (LLNM) in rectal cancer located below the peritoneal reflection, and to construct a corresponding predictive model.The main questions it aims to answer are: What factors are associated with clinically suspected lateral lymph node metastasis in rectal cancer below the peritoneal reflection? Can an effective predictive model be constructed based on these factors? Participants' clinical information has been collected for statistical analysis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 690 (actual)
- First submitted
- 11 Feb 2026
- Start date
- 1 Jan 2025
- Primary completion date
- 1 Sept 2025
- Lead sponsor
- First Affiliated Hospital of Fujian Medical University
- Diseases
- Colorectal cancer
- NCT number
- NCT07419516
What you commit to
- Study type: Observational
- Participants enrolled: 690
- From 1 Jan 2025 to the primary completion date, 1 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment for rectal cancer with chemotherapy, radiotherapy, or surgery, with the current presentation indicating recurrence
Other illness
- Pathological diagnosis of non-primary rectal malignancies
Other
- Incomplete rectal MRI data or poor image quality affecting interpretation
- Incomplete medical or clinical records. Ultimately, 690 patients were included in the final analysis
Who the study is looking for
- Age at diagnosis between 18 and 75 years
- Pathological confirmation of rectal adenocarcinoma by endoscopic biopsy
- Imaging confirmation that the tumor was located below the peritoneal reflection
- Availability of rectal MRI scans providing detailed imaging of the pelvic region
- Received treatment at The First Affiliated Hospital of Fujian Medical University between January 2022 and December 2024
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Fujian Medical University Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.